Loading stock data…
PHAR
$12.59-0.21 (-1.64%)
After Hours$12.58-0.01 (-0.08%)· Last close Jun 9
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pharming Group N.V. in the Healthcare sector is trading at $12.59. Wall Street consensus targets $34.35 (4 analysts), implying a +172.8% move over the next 12 months. The stock is currently 41% below its 52-week high of $21.34, remaining 20.0% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +172.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$12.59
Potential Downside
0%
Whystock Fair Value$12.59
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$34.35+172.8%
Range$23.40 – $40.00
Fundamentals
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RU...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
4.58%
Volume
Today's trading volume
4,066
Recent News
High Growth Tech Stocks in Europe with Promising Potential
The European market has shown resilience with the pan-European STOXX Europe 600 Index edging up slightly, as investors remain hopeful for geopolitical resolutions that could stabilize energy markets and boost economic confidence. In this environment, identifying high-growth tech stocks involves looking for companies with strong innovation capabilities and adaptability to current trends such as artificial intelligence and digital transformation, which can offer promising potential despite...
We Think Pharming Group's (AMS:PHARM) Profit Is Only A Baseline For What They Can Achieve
Even though Pharming Group N.V. ( AMS:PHARM ) posted strong earnings, investors appeared to be underwhelmed. We did...
Pharming Group N.V. Recorded A 21% Miss On Revenue: Analysts Are Revisiting Their Models
Shareholders in Pharming Group N.V. ( AMS:PHARM ) had a terrible week, as shares crashed 23% to €1.10 in the week since...
Pharming Group Q1 Earnings Call Highlights
Pharming Group (NASDAQ:PHAR) executives said first-quarter 2026 results reflected an expected decline in RUCONEST revenue tied largely to specialty pharmacy inventory movements and the company’s planned exit from certain non-U.S. markets, while Joenja continued to post strong growth and the company
High Growth Tech Stocks To Watch In May 2026
As global markets navigate the complexities of geopolitical tensions and shifting monetary policies, U.S. stocks have shown resilience with major indexes posting gains despite a hawkish Federal Reserve stance and fluctuating oil prices. In this context, identifying high-growth tech stocks involves looking for companies that demonstrate robust earnings potential and innovation in sectors like artificial intelligence, which are poised to benefit from current market dynamics.